A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011

Tomoko Betsuyaku, Motokazu Kato, Keisaku Fujimoto, Gerry Hagan, Akihiro Kobayashi, Hideki Hitosugi, Mark James, Paul W Jones, Tomoko Betsuyaku, Motokazu Kato, Keisaku Fujimoto, Gerry Hagan, Akihiro Kobayashi, Hideki Hitosugi, Mark James, Paul W Jones

Abstract

Background and objective: The Global initiative for chronic Obstructive Lung Disease (GOLD) Committee has proposed a chronic obstructive pulmonary disease (COPD) assessment framework focused on symptoms and on exacerbation risk. This study will evaluate a symptom and exacerbation risk-based treatment strategy based on GOLD in a real-world setting in Japan. Optimal management of COPD will be determined by assessing symptoms using the COPD Assessment Test (CAT) and by assessing the frequency of exacerbations.

Methods: This study (ClinicalTrials.gov identifier: NCT01762800) is a 24-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. It aims to recruit 400 patients with moderate-to-severe COPD. Patients will be randomized to receive treatment with either salmeterol/fluticasone propionate (SFC) 50/250 μg twice daily or with tiotropium bromide 18 μg once daily. Optimal management of patients will be assessed at four-weekly intervals and, if patients remain symptomatic, as measured using the CAT, or experience an exacerbation, they have the option to step up to treatment with both drugs, ie, SFC twice daily and tiotropium once daily (TRIPLE therapy). The primary endpoint of the study will be the proportion of patients who are able to remain on the randomized therapy.

Results: No data are available. This paper summarizes the methodology of the study in advance of the study starting.

Conclusion: The results of this study will help physicians to understand whether TRIPLE therapy is more effective than either treatment strategy alone in controlling symptoms and exacerbations in patients with moderate-to-severe COPD. It will also help physicians to understand the GOLD recommendation work in Japan.

Keywords: COPD; GOLD; TRIPLE therapy; exacerbation risk; symptom.

Figures

Figure 1
Figure 1
Study design. Abbreviations: SFC, salmeterol/fluticasone propionate; Tio, tiotropium bromide; TRIPLE, SFC twice daily and Tio once daily.

References

    1. The Japanese Respiratory Society . Guidelines for the Diagnosis and Treatment of COPD. 3rd ed. Tokyo: Japanese Respiratory Society; 2009.
    1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
    1. Global initiative for chronic Obstructive Lung Disease (GOLD) [homepage on the Internet] 2010Available from: Accessed March 25, 2013
    1. Global initiative for chronic Obstructive Lung Disease (GOLD) 2011Accessed March 25, 2013
    1. Global initiative for chronic Obstructive Lung Disease (GOLD) 2013Accessed March 25, 2013
    1. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–654.
    1. Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38:29–35.
    1. Tsuda T, Suematsu R, Kamohara K, et al. Development of the Japanese version of the COPD Assessment Test. Respir Investig. 2012;50:34–39.
    1. Ichinose M, Aizawa H, Ishizaka A, et al. [Chronic obstructive pulmonary disease (COPD) burden in Japan: confronting COPD Japan survey.] Nihon Kokyuki Gakkai Zasshi. 2007;45(12):927–935. Japanese [with English abstract]
    1. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9:458–465.
    1. Nakano Y, Nagai A, Mishima M, Yoshimoto D, Hagan G. [Investigation of COPD management in primary care in Japan using hand-held spirometer.] Kokyu. 2012;31:273–281. Japanese.
    1. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–555.
    1. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology. 2006;11:598–602.
    1. Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of ‘triple’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592–598.
    1. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741–750.
    1. Hanania NA, Crater GD, Morris AN, Emmett AH, O’Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91–101.
    1. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586.
    1. GlaxoSmithKline Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg [website on the Internet] Bethesda, MD: US National Library of Meicine; 2012[updated July 11, 2013]. Available from: . NLM identifier: NCT01762800Accessed August 28, 2013
    1. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S, EXACT-PRO Study Group Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011;183:323–329.
    1. Jones PW, Chen WH, Wilcox TK, Sethi S, Leidy NK, EXACT-PRO Study Group Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest. 2011;139(6):1388–1394.
    1. Leidy NK, Wilcox TK, Jones PW, et al. EXACT-PRO Study Group Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome measure. Value Health. 2010;13:965–975.
    1. Schmier JK, Halpern MT, Higashi MK, Bakst A. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual Life Res. 2005;14:329–347.
    1. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290(17):2301–2312.
    1. Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation: a systematic review. Int J Chron Obstruct Pulmon Dis. 2007;2:241–251.
    1. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5:44–49.
    1. Keene ON, Vestbo J, Anderson JA, et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J. 2009;34:1018–1023.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel